Many viewers of the 2025 Golden Globes quickly noticed stars who seemed to have embraced GLP-1 medications that help people ...

Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it could happen much sooner than later. The analysts pointed to ...

Zepbound’s superior efficacy and strategic market expansion suggest that the drug will dominate the obesity market, surpassing Novo Nordisk’s Wegovy (semaglutide), according to GlobalData ...

From heart and kidney health to addiction reduction, GLP-1 drugs like Ozempic and Mounjaro may help with more than just weight loss Steve Christo/Corbis/Corbis/Getty ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep ...

Even the most iconic brand occasionally finds itself at a crossroads. A strong identity can keep you relevant for decades, ...

CHARLESTON, W.Va. (AP) — Lory Osborn says the Wegovy she was prescribed 15 months ago did more than help her lose 75 pounds — over a quarter of her body weight. The administrative assistant at ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

The weight loss medication Ozempic has become the most talked-about drug in Hollywood, with several celebrities like Kyle Richards and Garcelle Beauvais denying that they’ve taken it to shed pounds.

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued sales growth ...

Surveillance programmes that monitor the UK's outbreak suggest flu hospital admissions are quadruple that of a month ago. Figures show more than 4,500 beds alone were taken up by flu patients ...